CMD-COAT®: A New Platform For Nanogel Innovation

Hydrophilic. Loadable. Durable. Scalable. Our patented nanogel platform is transforming medical device coatings — enabling multi-API delivery, superior passive protection, and a new approach to antimicrobial resistance. CMD-COAT® enhances device performance with exceptional coverage — all without disrupting existing manufacturing processes. Discover the innovations behind our solutions.

Behind the Breakthroughs

Advanced Coating Technology

Water-based Process

Our entire coating system — from formulation to process and application — is water-based. This creates a highly stable, biocompatible foundation with no need for aggressive solvents.

  • Multilayer, cross-linked nanogel coating
  • Nanogel structure remains intact — never released into the body
  • Strong covalent bonds
CM4Cure Liège CHU Sart Tilman Laboratoire
Platform for API Delivery - CM4Cure

Platform for API Delivery

Our advanced platform can be loaded with up to six APIs — both water-soluble or insoluble. The patented polymer system enables targeted, progressive release up to 30 days.

  • Supports 1–6 APIs in a single coating
  • Enables both soluble and insoluble compounds
  • Controlled release up to 30 days
  • Patented nanogel platform enhances device performance

Flexible. Durable. Compatible.

CMD-COAT® forms an ultra-thin layer with exceptional bonding strength. It works on extremely narrow diameters and adapts to even the most sensitive or complex devices without affecting flexibility or function.
  • Nanometer-thin layer
  • Strong adhesion
  • No surface damage or material degradation
  • Compatible with plastics, metals, and biological tissue
CM4CURE Nurse,Inputting,Catheter,For,Iv,Drip,In,Patient,Hand,Closeup
CM4Cure Liège CHU Sart Tilman

Passive Coating, Superior Protection

Even without APIs, CMD-COAT® provides best-in-class device protection. The hydrophilic coating resists fouling from blood, proteins, and microbes — constantly protecting device surfaces.
  • Superior antifouling performance
  • Limits surface buildup and contamination
  • Functions as a standalone protective barrier

Innovative APIs

Novel Mode of Action

A century after penicillin, we’re entering a new era of antibiotics. Our patented pyrimidine-based APIs reinvent how we target the bacterial cell wall — hitting multiple points to shut down even the toughest drug-resistant infections. This pleiotropic mechanism disrupts antimicrobial resistance, stopping infections at the source. CM4CURE

  • Multiple cell wall targets
  • Pleiotropic effects break resistance mechanisms
  • Effective in preventing and treating difficult infections caused by both Gram-positive and Gram-negative bacteria

Engineered to Outpace Resistance

Antibiotic resistance is rising — turning manageable infections into serious threats. Our APIs work with antibiotics to enhance their effect, lower required doses, and have shown strong results in major clinical trials — with no known resistance. 

  • Boosts antibiotic effectiveness
  • Enables lower antibiotic dosages
  • Clinically proven results
  • No known resistance
CM4Cure Liège CHU Sart Tilman étude en Laboratoire

Fluometacyl®: Dual-action API

Our patented API is built from a metabolite of an FDA-approved drug with full toxicology data. It delivers strong efficacy without added regulatory burden. When Fluometacyl® is paired with CMD-COAT®, it produces the first dual-action coating with both antimicrobial and antithrombotic properties.
  • First-of-its-kind antimicrobial and antithrombotic coating
  • Proven synergy from known, safe components
  • No added regulatory or chemical complexity
CM4Cure Liège CHU Sart Tilman test en Laboratoire

Future Applications

Medical device coatings are just the beginning. Our APIs are built for two key paths: 

  • Coating applications using FDA-derived API combinations — safe, effective, and ready for clinical use.
  • Pharmaceutical development of novel antimicrobial APIs — targeting resistant infections through topical, oral, nebulized, and IV delivery.
CM4CURE RESEARCH & DEVELOPMENT

Manufacturing-Ready. Scalable by Design.

CMD-COAT® was engineered not just for performance, but for seamless integration into medical device manufacturing — with no added time, complexity, or environmental burden.

Water-Based, Solvent-Free Process

Our entire coating technology is built around a water-based process. That means no solvents, no special curing, and no additional risk to operators or the environment.
Solvent-free formulation

Water-based mixing and application

Room temperature processing

No UV curing, thermal treatment, or post-processing required

More ecofriendly than solvent-based systems

Fast, Simple, and Familiar

CMD-COAT® requires no complex chemical reactions during application. Coating time matches current industry best practices — so there’s no retooling or slowing down the line.
Coating process completes in 24 hours
No change to production timelines Pre-mixed materials — no on-site chemistry required Easy adoption with existing workflows

Wide Material Compatibility

The coating forms a stable bond across a broad range of materials — including plastics, metals, and biological tissues. It provides long-lasting medical device protection without degrading surfaces or affecting performance.
Bonds to plastics, metals, and biological tissues

Ultra-thin yet durable layer

No material deterioration

Maintains flexibility and function

Full Coverage - Inside and Out

CMD-COAT® delivers complete surface protection — covering both interior and exterior surfaces, even on complex device geometries.
Compatible with standard methods like dip-coating and flow-coating, it reliably coats even the narrowest internal diameters, including multi-lumen catheters.

Solving Critical Risks in IV Catheters

Bloodstream infections from IV catheters can cost up to $46,000 per episode and carry a 15% mortality rate. Thrombosis affects up to 18% of patients, compounding risk and driving up costs. Existing coatings offer limited protection. CMD-COAT® goes further. Paired with our patented Fluometacyl® API, it delivers first-of-its-kind dual protection against both infection and thrombosis — all in a single, ultra-thin, hydrophilic layer. CMD-COAT®is designed to scale across insertable and implantable devices — and beyond. CM4CURE

0.1% - 9%

$46k per episode
15% Mortality

Bloodstream Infection

5% - 18%

$5k per episode
Increased Infection Risk

Thrombosis

Expanding What’s Possible

IV catheters are just the beginning. Our nanogel platform, CMD-COAT®, is designed to enhance safety and performance across a wide range of medical devices — from high-risk insertables to long-term implants. Potential applications span:
  • Urinary Catheters
  • Port-a-Cath IV Access
  • Heart Valve Implants
  • Prosthesis
  • Hemodialysis Catheters
  • Breast Implants
  • Stents
  • Pacemakers

With programmable API delivery, exceptional passive protection, and potential for new API formats, it’s a new frontier for coating technology.

Meet the Team

Behind this revolutionary platform is a team of leading clinicians, scientists, engineers, and business strategists working to change the future of medical device coatings and patient care.

FIND OUT ABOUT US